At-a-Glance:
| Company |
Cytiva |
|---|
| Specialties |
Life science solutions including bioprocessing, single-use technologies, chromatography, cell and gene therapy manufacturing, mRNA technologies, and advanced biopharmaceutical process development and optimization. |
|---|
| Mission |
At Cytiva, the mission is to advance and accelerate the development of therapeutics. The company’s broad and deep portfolio of tools and technologies provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. |
|---|
| Noteworthy |
Cytiva is a Danaher company |
|---|
| Location |
Marlborough, MA |
|---|
| CEO |
Chris Riley |
|---|
Cytiva stands as a global powerhouse in the life sciences industry, playing a pivotal role in advancing and accelerating the development and manufacture of therapeutics. With a heritage spanning hundreds of years, Cytiva is a key player, providing technologies and services that support the entire lifecycle of drug development, from discovery to delivery.
The company's journey took a significant turn in 2020 when it emerged from GE Healthcare Life Sciences following a $21.4 billion acquisition by Danaher Corporation. This transition positioned Cytiva as a new operating company within the Danaher Life Sciences platform, allowing it to leverage existing expertise while exploring new avenues for growth and innovation.
Operating on a global scale, Cytiva maintains a presence in over 41 countries and employs over 15,000 associates worldwide. This extensive network enables the company to serve a diverse range of customers, from researchers and emerging biotech firms to large-scale biopharmaceutical companies and contract manufacturers.
Cytiva's portfolio encompasses a wide array of well-recognized brands and technologies catering to various aspects of life sciences research and biopharmaceutical manufacturing. These include ÄKTA™ chromatography systems, Amersham™ products for protein analysis, Biacore™ systems for interaction analysis, FlexFactory™ biomanufacturing platforms, HyClone™ cell culture media, MabSelect™ affinity resins, Pall filtration products, Whatman™ filters, devices, membranes, and Xcellerex™ single-use bioreactors.
The company's core capabilities span several key areas within life sciences, including bioprocessing, cell culture, protein analysis, and diagnostics. Cytiva also provides comprehensive services and support, offering equipment services, regulatory support, and training programs to help customers throughout their research and manufacturing processes.
In conclusion, Cytiva stands as a significant contributor to the life sciences and biopharma sectors, leveraging its extensive history, global reach, and diverse portfolio to help improve patient outcomes. From providing essential tools and technologies to fostering collaboration and innovation, Cytiva plays a vital role in shaping the future of therapeutic development and manufacturing.